• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Raymond James initiated coverage on Avidity Biosciences with a new price target

    6/11/25 7:52:47 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RNA alert in real time by email
    Raymond James initiated coverage of Avidity Biosciences with a rating of Strong Buy and set a new price target of $65.00
    Get the next $RNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RNA

    DatePrice TargetRatingAnalyst
    6/17/2025$55.00Outperform
    Wolfe Research
    6/11/2025$65.00Strong Buy
    Raymond James
    3/13/2025$70.00Buy
    Citigroup
    3/12/2025$72.00Outperform
    BMO Capital Markets
    3/7/2025$70.00Sector Outperform
    Scotiabank
    12/20/2024$72.00Buy
    H.C. Wainwright
    11/26/2024$67.00Outperform
    RBC Capital Mkts
    9/24/2024$59.00Buy
    Goldman
    More analyst ratings

    $RNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Program Officer Gallagher Kathleen P. sold $27,549 worth of shares (911 units at $30.24), decreasing direct ownership by 2% to 50,392 units (SEC Form 4)

      4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

      6/18/25 6:02:48 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Henig Noreen was granted 6,692 shares (SEC Form 4)

      4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

      6/12/25 6:42:47 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Boess Carsten was granted 6,692 shares (SEC Form 4)

      4 - Avidity Biosciences, Inc. (0001599901) (Issuer)

      6/12/25 6:40:46 PM ET
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care